Miller Rosalind, Goodman Catherine
Department of Global Health and Development, London School of Hygiene and Tropical Medicine, 15-17 Tavistock Place, London, WC1H 9SH, United Kingdom.
J Clin Tuberc Other Mycobact Dis. 2019 Dec 2;18:100135. doi: 10.1016/j.jctube.2019.100135. eCollection 2020 Feb.
Pharmacies hold great potential to contribute meaningfully to tuberculosis (TB) control efforts, given their accessibility and extensive utilisation by communities in many high burden countries. Despite this promise, the quality of care provided by pharmacies in these settings for a range of conditions has historically been poor. This paper sets out to conceptualise the key issues surrounding quality of TB care in the low- and middle-income country pharmacy setting; examine the empirical evidence on quality of care; and review the interventions employed to improve this. A number of quality challenges are apparent in relation to anti-TB medicine availability, pharmacopeial quality of anti-TB medicines stocked, pharmacy workers' knowledge, and management of patients both prior to and following diagnosis. Poor management practices include inadequate questioning of symptomatic patients, lack of referral for testing, over-the-counter sale of anti-TB medication as well as unnecessary and harmful medicines (e.g., antibiotics and steroids), and insufficient counselling. Interventions to improve pharmacy practice in relation to TB control have all fallen under the umbrella of public-private mix (PPM) initiatives, whereby pharmacies are engaged into national TB programmes to improve case detection. These interventions all involved training of pharmacists to refer symptomatic patients for testing and have enjoyed reasonable success, although achieving scale remains a challenge. Future interventions would do well to expand their focus beyond case detection to also improve counselling of patients and inappropriate medicine sales. The lack of pharmacy-specific global guidelines and the regulatory environment were identified as key areas for future attention.
鉴于在许多高负担国家,药房具有可及性且社区广泛使用,因此药房在结核病(TB)防控工作中具有做出重大贡献的巨大潜力。尽管有此前景,但在这些环境中,药房针对一系列病症所提供的护理质量历来较差。本文旨在对低收入和中等收入国家药房环境中结核病护理质量的关键问题进行概念化;研究护理质量的实证证据;并回顾为改善护理质量所采用的干预措施。在抗结核药物供应、所储备抗结核药物的药典质量、药房工作人员的知识以及诊断前后患者的管理方面,存在一些明显的质量挑战。不良管理做法包括对有症状患者的询问不足、缺乏检测转诊、抗结核药物以及不必要和有害药物(如抗生素和类固醇)的非处方销售,以及咨询不足。为改善与结核病防控相关的药房实践所采取的干预措施均属于公私合营(PPM)倡议的范畴,即药房参与国家结核病规划以改善病例发现。这些干预措施都涉及对药剂师进行培训,以便将有症状患者转诊进行检测,并且取得了一定的成功,尽管实现规模效应仍然是一项挑战。未来的干预措施最好将重点从病例发现扩展到改善患者咨询和不当药品销售。缺乏针对药房的全球指南以及监管环境被确定为未来需要关注的关键领域。